TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback